BMT-13
A Phase II Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Myeloablative Fludarabine/Busulfan and Post-Transplant Cyclophosphamide (PTCY) for Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients with High-Risk AML, CML, and MDS
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 38 patients (estimated)
- Sponsors
- University of Illinois at Chicago
- Tags
- Pre-Allogeneic Stem Cell Transplant, Radiation Therapy
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 2057
- NCT Identifier
- NCT06802315
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.